Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia [Phase 3]

View source ↗

Summary

A Phase 3 study of Infigratinib in children and adolescents with achondroplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achondroplasia

Drugs mentioned

• Infigratinib (infigratinib)

Snippet

Sponsor: QED Therapeutics, a BridgeBio company | Conditions: Achondroplasia | Phase 3 | Status: COMPLETED